A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study.
Mark S SulkowskiJuhi S MoonKenneth E ShermanGiuseppe MorelliJama M DarlingAndrew J MuirMandana KhaliliDawn A FishbeinFederico HinestrosaMitchell L ShiffmanAdrian Di BisceglieK Rajender ReddyBrian PearlmanAnna S LokMichael W FriedPaul W StewartJoy PeterSummer WadsworthScott KixmillerAnquenette SloanMonika VainoriusPatrick M HorneLarry MichaelMeichen DongDonna M EvonJodi B SegalDavid R Nelsonnull nullPublished in: Hepatology (Baltimore, Md.) (2021)
This pragmatic trial demonstrated high SVR12 for participants treated with EBR/GZR and LDV/SOF with few adverse effects. Overall, the two regimens were equivalent in effectiveness. The results support current HCV guidelines that do not distinguish between ribavirin-free EBR/GZR and LDV/SOF.